Investigational drug · Phase 2
JB100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Urothelial Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "JB100"
First trial start
2022
Aug 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JB100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Urothelial Carcinoma
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JB100" as an intervention, largest first.
- A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Pivotal-lookingActive, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT05327530 · 256 participants · Start Aug 17, 2022 · Primary completion Jun 20, 2025
Drug: Avelumab; Sacituzumab Govitecan (SG) and 3 more · For: Locally Advanced or Metastatic Urothelial Carcinoma
Sites: Coeur d'Alene, Idaho; Kansas City, Kansas; Baltimore, Maryland · 98 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.
Dillon R, Jones R, Fléchon A, et al. · Eur Urol Oncol 2026
- Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
Bellmunt J, Chang J, Pavilack-Kirker M, et al. · Clin Genitourin Cancer 2023
Also in development for Locally Advanced or Metastatic Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.